Filing Details
- Accession Number:
- 0001209191-23-019879
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-17 18:17:06
- Reporting Period:
- 2023-03-15
- Accepted Time:
- 2023-03-17 18:17:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1819790 | Tarsus Pharmaceuticals Inc. | TARS | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1788542 | Aziz Mottiwala | C/O Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160 Irvine CA 92618 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-03-15 | 4,790 | $0.00 | 54,940 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-03-16 | 336 | $13.43 | 54,604 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2023-03-15 | 4,790 | $0.00 | 4,790 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 14,370 | No | 4 | M | Direct |
Footnotes
- The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
- Includes 421 shares acquired under the Issuer's employee stock purchase plan on December 31, 2022.
- The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- Each RSU represents a contingent right to receive one share of the Company's common stock.
- RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.
Billionaire Hedge Funds
